The year ahead
Year 2009 promises to be a 'Year of Consolidation'
for life sciences industry in the Asia Pacific region. While Big pharma
will continue to downsize as patents expire and new products come to
market slower, biotech companies will learn to sell their IP cheaply,
merge, find synergies or die as they run out of money. The year rings
in consolidation with capital “C�
The US economy has entered a prolonged period of recession
and will remain weak for most parts of 2009. This will possibly extend
into 2010. It is likely that the conditions experienced in 2008
(limited availability of capital from debt and equity markets) will
continue to persist. According to Dr Louis Payet, Senior Consultant,
Healthcare Asia Pacific, Frost & Sullivan, the capital
availability for small-to-mid size development stage life sciences
companies will lag the broader market and these industries will remain
under funding-pressure for a significant period of time.
He says, even though year 2009 will remain challenging for companies in
the healthcare sector due to declining government expenditure and
weakness in the healthcare insurance sector the industry in Asia, in
2009, will continue to grow. Stagnant and challenging markets in the US
(and EU) will drive the companies in these regions to increase their
focus on growing Asian markets. The financial crisis will however
broadly slow the growth of the region's major markets such as
China and India.
The overriding factor that will modulate the growth of the sector in
Asia will be access to funding. Even though US, EU and Japanese
companies may see the region as critical to their growth, their ability
to develop their operations here will to a great extent be determined
by their access to funding. Small-to-mid size Asian companies with
access to strong customer bases, manufacturing capabilities or
innovative products will fare better. Also, a continued drive towards
personalized medicines is likely to result in the emergence of new
technologies in the diagnostics and medical IT space. Diagnostic
technologies providing patient specific analysis (such as
characterizing drug resistance in infectious disease suffers) will see
increasing demand due to their ability to improve patient therapeutic
outcomes. The need to streamline the analysis of large amounts of
patient data will also drive the development of complementary IT
systems designed to support large scale data analysis and the
subsequent automated output of concise analytical reports. These
systems will provide medical practitioners with timely results that can
be used to make patient specific treatment decisions. This trend
towards 'personalized medicine' will be encouraged
by governments, as optimal application of costly therapeutics can
result in lower healthcare costs.
In the following pages of this special issue, BioSpectrum fast forwards
2009 to capture a first person account of what the industry insiders
are anticipating in the year ahead.
Forced M&As will rise:
Burrill
Year 2009 is a time of great opportunity and many changes. Overall, the
industry will see consolidation, a forced consolidation at that. There
will be hectic M&A activity and outsourcing to Asia will pick
up speed. India and China will rise as the preferred R&D
destination. The year 2009 will also see reduced research and
development spending and fewer and expensive capital raising
If I look at the projections that I have done in the last 10 years, I
have been spot on. They have all been 100 percent correct. Earlier, in
2008, I said this will be a boom year for mergers and acquisitions and
it was. One of my projections for 2008 that shocked many was the
implosion of the capital market and the bust after that. We have been
very accurate in our projections on industry, change in the economic
environment and so on.
I see year 2009 to be a challenging year. I am not writing the obituary
for the year or for the industry or the transactions. In currency
terms, there will be more transactions done, more deals done globally
but these will be of different scale and not of the same type in dollar
terms. These will be very different from what we have seen so far.
Forced M&As will
rise
To be able to say what is going to happen in the R&D and
M&A arena in 2009, you have to put the backdrop in perspective.
You have to consider the last year. In 2008, there were two
halves-the first half where the economy actually tanked, and
the second half where we had to deal with the massive downturn. In the
second half of 2008, we had a substantially reduced capital regime
where we had just one IPO in the US and a few elsewhere in the
biomedical arena. We had a reduced capital spending period and broadly
tougher economic environment. We had relatively few big deals and
R&D spending had
come down.
In 2009, we will see reduced R&D spending, lower, fewer and
more expensive capital raising activities. Power of the entrepreneurs
to raise capital will be greatly reduced.
Going forward, we will see consolidation. We will see M&As
forced on companies on some reasonably attractive terms. However, there
will be some others who will file for bankruptcy and call it quits. We
will see attractive deals in the higher end of spectrum and the action
moving to the global stage like Indian companies doing business with
Indian companies and Indian companies doing business with Chinese
companies.
Business models will
change
The pharma model that you and I have known historically is in for a big
change. We will see big companies disintegrating or selling away parts
of their companies or spinning-off parts of their company into new
companies. We will see integration of different slices of the value
chain and change in business models. We will see companies merging with
equals and keeping products that sell and getting rid of products that
don't make sense. We will also see big companies buying big
and small companies, biotechs buying small companies and small
companies itself coming together.
We will see consolidation all across along with a high level of
M&A activity.
Outsourcing to Asia will
rise
Outsourcing to Asia will pick up speed. We will see more healthcare
expansion in Asia-India and China in particular. We will see
more entrepreneurship and innovation in Asia. Both large and small
markets in Asia will benefit from a relatively changing world.
Obama to inject life into
the industry (exclusively as told to Sanjeev Jain, )
The Obama administration will be positive for the US and the world. The
new administration will bring in positive changes. Healthcare reform is
on priority for the Obama administration. These will give stimulus to
the industry.
Healthy
growth ahead, in spite of slowdown: KPMG
The Asia Pacific (APAC) pharma and biotech segments of the life
sciences Industry has attracted substantial interest from global
players in the industry and already is, (inclusive of Japan), the third
largest regional market after North America and Europe. The percentage
of Asia's population defined as elderly is increasing very
rapidly. There are industry estimates which suggest that as much as $50
billion will be injected into the Asia Pacific life sciences markets
from both public and private sources over the next few years. The race
is clearly on among Asia Pacific countries as they seek to position
themselves as genuine global pharma and bio-environments.
The success of Asian pharmaceutical companies can be attributed to
their low cost, high quality advantage that made them leading
suppliers/ exporters of Active Pharmaceutical Ingredients (APIs) and
formulations globally. The biopharma segment accounts for a major share
in the APAC biotech market and the region is expected to become a major
destination for stem cell research and biogeneric manufacturing. It is
also expected to play a dominant role in the antibody therapeutics
development. Major focus is being centered on gene therapy,
agri-sciences, bioinformatics, genomics and proteomics.
Growth in the scientific advancement and capabilities clubbed with a
very large patient pool (Asia accounts for more than 60 percent of the
world's population) marks Asia as one of the preferred
partner of choice. The APAC region as a whole and predominantly India
and China have emerged as favored off shoring/ outsourcing destinations
for various pharmaceutical activities like Contract Research and
Manufacturing Services, (CRAMS), and Clinical Trial Services. Given the
opportunities on offer, many countries in the APAC region have
expressed their intent to become pharma and/ or biotech hubs and
countries like Australia, Japan, South Korea, China, Singapore, India,
Taiwan, Malaysia, Hong Kong and others have set up growth plans for
this sector. They have set up pharma and biotech clusters, sometimes
with government support for research, in order to enhance their
industry capabilities. For example, China is already the largest
vaccine manufacturing country in the world. Many big Indian pharma
companies have also started venturing into biotech.
India has the third largest pool of technically qualified manpower,
which augurs well for the need for larger numbers of skilled human
resources, which will be required to keep fuelling the growth in these
knowledge-based industries.
Apart from this, the regulatory environment in Asia Pacific countries
particularly in India, China and Japan are at par with global standards
as well as the availability of skilled manpower and infrastructure has
also contributed towards the success of this region. The recent reforms
in the area of Intellectual Property (IP) protection have further
instilled confidence and MNCs are now investing heavily in this region.
The APAC pharma market is expected to grow by 9 to 12 percent over
2006-2010 as compared to North America and European markets that are
expected to grow at five to eight percent. Some of the key markets
within the Asia Pacific region include China, India, Japan, South
Korea, Taiwan and Australia. Smaller regions like Singapore, Malaysia
and Vietnam are also budding markets within this region.
The biotech market in the APAC region is further expected to grow by 10
percent in 2008, with Japan making the largest contribution. Some of
the key markets in this region include Japan, China, Australia and
India. The Korean government is aiming to join the world's
top seven biotechnology powers by 2010, Taiwan is earmarking three
percent of GDP for life science development and Singapore wants to have
an increasing share of the global scientific community. China is also
making a concerted effort to raise the standard and profile of its
local biotechnology industry.
The APAC region has also succeeded in capturing a larger pie of the
global pharmaceutical and biotech industries on account of a large
number of global pharma companies resorting to cost cutting measures
due to mounting cost pressures and relocating their manufacturing and
research bases to this region. Even as MNCs are setting up their
operations in Asia, the domestic APAC companies are constantly
expanding their global reach and are acquiring a larger share in the
international markets.
Crystal ball gazing into 2009, one can expect the market to grow
further in spite of the global economic slowdown on the basis of
increase in the demand for pharmaceutical and biotech products that
would largely be driven by rapid growth of population and longer life
expectancy coupled with changing lifestyle pattern due to increased
urbanization and changing demographics will contribute to a healthy
clip in sales growth.
Outsourcing to Asia
will intensify:PwC
Sujay.gif |
With the US downturn, the movement of business to Asia will intensify.
Cash rich Big pharmas will be making an effort to boost their
stagnating R&D pipeline and will be the key driver in increased
outsourcing to Asia. Contract Research and Manufacturing Services space
(CRAMS) will also see a spurt in investments.
In the M&As arena big pharma will be focused on two things:
augmenting their R&D pipeline and increasing their exposure to
India and China. With valuations correction and stock prices coming to
their realistic prices, a good number of deals are just waiting to
happen.
If you look at international scenario, acquisition activity has been
quite strong when it comes to MNCs buying out smaller yet innovative
biotech or pharma companies and could even see big pharma firms
acquiring or merging with equally big rival. This is a very likely
possibility in 2009.
Another possibility is consolidation amongst small and medium sized
firms. Among the SME players, merging their strengths to survive is a
route many will take. They will take this route to progress their
research and compounds to positive results.
Year of Consolidation
Nandita Singh, Narayan
Kulkarni, Sanjeev Jain & Shruthi Ram